Related Experiment Video

Updated: Apr 17, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

[Tasquinimod: How to act on microenvironment in metastatic prostate cancer]

N Houédé1, J Irani2

  • 1Oncologie médicale, CHU Caremeau, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|February 17, 2015
PubMed

Insights

Tasquinimod shows promise for castration-resistant metastatic prostate cancer (mCRPC) by targeting tumor microenvironment. Phase II trials indicate over 50% improvement in progression-free survival with acceptable tolerance.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Castration-resistant metastatic prostate cancer (mCRPC) presents a significant therapeutic challenge with a poor prognosis.
  • Existing treatments have limitations, highlighting the urgent need for novel therapeutic strategies.

Purpose of the Study:

  • To review the preclinical and clinical data of tasquinimod, an orally administered drug.
  • To emphasize the unique mechanism of action of tasquinimod in targeting the tumor microenvironment.

Main Methods:

  • Review of preclinical studies and clinical trial data for tasquinimod.
  • Focus on a phase II double-blind randomized study comparing tasquinimod to placebo in mCRPC patients.

Main Results:

  • Tasquinimod targets both angiogenic and immune components of the tumor microenvironment.
  • Specifically, it modulates S100A9 protein to restore immunity and reduce angiogenesis.
  • Phase II study demonstrated over 50% improvement in progression-free survival for mCRPC patients treated with tasquinimod compared to placebo.
  • Tasquinimod exhibited acceptable safety and tolerability at a 1mg/day dose.

Conclusions:

  • Tasquinimod represents a novel therapeutic approach for mCRPC.
  • Its dual action on angiogenesis and immunity offers a promising strategy for improving patient outcomes.
Keywords:
AngiogenesisAngiogenèseCancer de prostate échappant à la castrationCastration-resistant prostate cancerImmunomodulationMicroenvironmentMicroenvironnementTasquinimod

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.1K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.2K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

3.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K